Boehringer In­gel­heim, Evotec band with di­ag­nos­tics play­er to tack­le 'su­per­bugs' through joint ven­ture

Hav­ing of­fered fi­nan­cial sup­port to com­pa­nies de­vel­op­ing an­tibi­otics and fight­ing an­timi­cro­bial re­sis­tance, Boehringer In­gel­heim is launch­ing its own.

The Ger­man phar­ma is team­ing up with Evotec — the drug dis­cov­ery and de­vel­op­ment play­er with whom it al­ready has a long-run­ning R&D al­liance in oth­er ar­eas — and French di­ag­nos­tic com­pa­ny bio­Mérieux to start a joint ven­ture that will cre­ate both next-gen an­timi­cro­bials and di­ag­nos­tics to tack­le in­fec­tious dis­eases.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER